ANI Pharmaceuticals (ANIP) reported $247.06 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 29.6%. EPS of $2.33 for the same period compares to $1.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $232.98 million, representing a surprise of +6.04%. The company delivered an EPS surprise of +17.32%, with the consensus EPS estimate being $1.99.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares are down early Friday following the company’s strong fourth-quarter report.ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the consensus estimate of $231.53 million.The Rare Disease segment, which includes products like Cortrophin Gel, saw ...

分组1 - ANI Pharmaceuticals reported quarterly earnings of $2.33 per share, exceeding the Zacks Consensus Estimate of $1.99 per share, and showing an increase from $1.63 per share a year ago, resulting in an earnings surprise of +17.32% [1] - The company achieved revenues of $247.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.04% and increasing from $190.57 million year-over-year [2] - ANI has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market with a decline of about 2.3% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $200.02 million, and for the current fiscal year, it is $8.22 on revenues of $1.07 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which ANI belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for ANI was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChristopher Mutz - SVP and Head of Rare DiseaseCourtney Mogerley - Managing DirectorGlen Santangelo - Managing DirectorLeszek Sulewski - VP of Spec Pharma and Biotech Equity ResearchNikhil Lalwani - President and CEOStephen Carey - SVP and CFOVamil Divan - Managing DirectorConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystThomas ...

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChristopher Mutz - SVP and Head of Rare DiseaseCourtney Mogerley - Managing DirectorGlen Santangelo - Managing DirectorLeszek Sulewski - VP of Spec Pharma and Biotech Equity ResearchNikhil Lalwani - President and CEOStephen Carey - SVP and CFOVamil Divan - Managing DirectorConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystThomas ...

ANI Pharmaceuticals (NasdaqGM:ANIP) Q4 2025 Earnings call February 27, 2026 08:00 AM ET Speaker8Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help you. Thank you for your continued patience. Your meetin ...

February 27, 2026 4Q and Full-Year 2025 Earnings Results Call © 2026 ANI Pharmaceuticals, Inc. 1 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that are not historical facts, including statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward- l ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-31812 ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 58-2301143 (State or other j ...

Core Insights - ANI Pharmaceuticals experienced significant growth in 2025, particularly in its Rare Disease and Generics segments, leading to an increase in both revenue and net income [2][7][10]. Financial Performance - Total net revenues for Q4 2025 reached $247.1 million, a 29.6% increase year-over-year, while full-year revenues were $883.4 million, up 43.8% [7][9]. - Rare Disease revenues for Q4 2025 were $131.3 million, reflecting a 50.8% increase year-over-year, with Cortrophin Gel contributing $111.4 million, an 87.6% increase [10][8]. - Generics net revenues were $100.8 million in Q4 2025, a 28.2% increase from the previous year, and $384.1 million for the full year, up 27.6% [4][11]. Product Highlights - Cortrophin Gel's growth was driven by new patient starts and an expanded sales force, with plans to enhance the Rare Disease organization by approximately 90 personnel to target acute gouty arthritis [8][10]. - ILUVIEN generated $19.8 million in Q4 2025 and $74.9 million for the full year, with ongoing commercial initiatives to improve patient access [8][10]. Profitability Metrics - GAAP net income for Q4 2025 was $27.5 million, or $1.18 per diluted share, compared to a net loss of $10.7 million in the prior year [15]. - Adjusted non-GAAP EBITDA for Q4 2025 was $65.4 million, a 30.6% increase year-over-year, driven by higher revenues and gross profit [16]. Guidance for 2026 - The company anticipates total net revenues for 2026 to be between $1,055 million and $1,115 million, representing a growth of 19% to 26% compared to 2025 [19]. - Cortrophin Gel is expected to generate revenues between $540 million and $575 million in 2026, indicating a growth of 55% to 65% [19].

Key Takeaways ANI Pharmaceuticals reports Q4 2025 earnings Feb. 27, with sales seen at $233M and EPS at $1.99.ANIP's Cortrophin Gel sales are expected at $114M, driven by 88% year-over-year growth.ANIP trades at 1.98x P/S, below the industry's 2.50x, with growth led by rare disease drugs.ANI Pharmaceuticals (ANIP) is set to report fourth-quarter and full-year 2025 earningson Feb. 27, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $233 million and $1.9 ...